Prognostic polypeptide blood plasma biomarkers of alzheimer's disease progression

Journal of Alzheimer's Disease

Volumn 40, Issue 3, 2014, Pages 659-666

  Yang, Hongqian ^a   Lyutvinskiy, Yaroslav ^a   Herukka, Sanna Kaisa ^b   Soininen, Hilkka ^b   Rutishauser, Dorothea ^a   Zubarev, Roman A ^a,c  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UNIVERSITY OF EASTERN FINLAND   (Finland)

^c SCIENCE FOR LIFE LABORATORY   (Sweden)

Author keywords

Biomarkers; human blood plasma; label free quantification; mass spectrometry

Indexed keywords

ALPHA 2 MACROGLOBULIN; BIOLOGICAL MARKER; PLASMA PROTEIN; POLYPEPTIDE; PEPTIDE; PROTEIN;

AGED; ALZHEIMER DISEASE; ARTICLE; BLOOD SAMPLING; CLINICAL ASSESSMENT; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; OUTCOME ASSESSMENT; PLASMA; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEOMICS; SEX DIFFERENCE; BLOOD; COHORT ANALYSIS; DISEASE COURSE; MASS SPECTROMETRY; METABOLISM; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; BIOLOGICAL MARKERS; BLOOD PROTEINS; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MASS SPECTROMETRY; MILD COGNITIVE IMPAIRMENT; PEPTIDES; PROTEINS; SEX FACTORS;

EID: 84901943933     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-132102     Document Type: Article

References (34)

1. Humpel C (2011) Identifying and validating biomarkers for Alzheimer's disease. Trends Biotechnol 29, 26-32.
2. Troncoso JC, Cataldo AM, Nixon RA, Barnett JL, Lee MK, Checler F, Fowler DR, Smialek JE, Crain B, Martin LJ, Kawas CH (1998) Neuropathology of preclinical and clinical lateonset Alzheimer's disease. Ann Neurol 43, 673-676. (Pubitemid 28225562)
3. Perrin RJ, FaganAM, HoltzmanDM(2009) Multimodal techniques for diagnosis and prognosis of Alzheimer's disease. Nature 461, 916-922.
4. Hyman BT, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Carrillo MC, Dickson DW, Duyckaerts C, Frosch MP, Masliah E, Mirra SS, Nelson PT, Schneider JA, Thal DR, Thies B, Trojanowski JQ, Vinters HV, Montine TJ (2012) National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimers Dement 8, 1-13.
5. BlennowK(2004) CSF biomarkers for mild cognitive impairment. J Intern Med 256, 224-234. (Pubitemid 39222991)
6. Andreasen N, Blennow K (2005) CSF biomarkers for mild cognitive impairment and early Alzheimer's disease. Clin Neurol Neurosurg 107, 165-173.
7. Lista S, Faltraco F, Prvulovic D, Hampel H (2013) Blood and plasma-based proteomic biomarker research in Alzheimer's disease. Prog Neurobiol 101-102, 1-17.
8. Ray S, Britschgi M, Herbert C, Takeda-Uchimura Y, Boxer A, Blennow K, Friedman LF, Galasko DR, Jutel M, Karydas A, Kaye JA, Leszek J, Miller BL, Minthon L, Quinn JF, Rabinovici GD, Robinson WH, Sabbagh MN, So YT, Sparks DL, Tabaton M, Tinklenberg J, Yesavage JA, Tibshirani R, Wyss-Coray T (2007) Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nat Med 13, 1359-1362. (Pubitemid 350073592)
9. Marksteiner J, Kemmler G, Weiss EM, Knaus G, Ullrich C, Mechtcheriakov S, Oberbauer H, Auffinger S, Hinterh?olzl J, Hinterhuber H, Humpel C (2011) Five out of 16 plasma signaling proteins are enhanced in plasma of patients with mild cognitive impairment and Alzheimer's disease. Neurobiol Aging 32, 539-540.
10. Furney SJ, KronenbergD, Simmons A,G?untert A, Dobson RJ, Proitsi P,Wahlund LO, Kloszewska I, Mecocci P, Soininen H, Tsolaki M, Vellas B, Spenger C, Lovestone S (2011) Combinatorial markers of mild cognitive impairment conversion to Alzheimer's disease - cytokines and MRI measures together predict disease progression. J Alzheimers Dis 26, 395-405.
11. Bazenet C, Lovestone S (2012) Plasma biomarkers for Alzheimer's disease: Much needed but tough to find. Biomark Med 6, 441-454.
12. Surinova S, Schiess R, Huttenhain R, Cerciello F,Wollscheid B, Aebersold R (2010) On the development of plasma protein biomarkers. J Proteome Res 10, 5-16.
13. Lyutvinskiy Y, Yang H, Rutishauser D, Zubarev RA (2013) In silico instrumental response correction improves precision of label-free proteomics and accuracy of proteomics-based predictive models. Mol Cell Proteomics 12, 2324-2331.
14. Hye A, Lynham S, Thambisetty M, Causevic M, Campbell J, Byers HL, Hooper C, Rijsdijk F, Tabrizi SJ, Banner S, Shaw CE, Foy C, Poppe M, Archer N, Hamilton G, Powell J, Brown RG, Sham P, Ward M, Lovestone S (2006) Proteome-based plasma biomarkers for Alzheimer's disease. Brain 129, 3042- 3050. (Pubitemid 44684524)
15. Thambisetty M, Lovestone S (2010) Blood-based biomarkers of Alzheimer's disease: Challenging but feasible. Biomark Med 4, 65-79.
16. Oresic M, Hyotylainen T, Herukka SK, Sysi-Aho M, Mattila I, Seppanan-Laakso T, Julkunen V, Gopalacharyulu PV, Hallikainen M, Koikkalainen J, Kivipelto M, Helisalmi S, Lotjonen J, Soininen H (2011) Metabolome in progression to Alzheimer's disease. Transl Psychiatry 1, e57.
17. Yang H, Lyutvinskiy Y, Soininen H, Zubarev RA (2011) Alzheimer's disease and mild cognitive impairment are associated with elevated levels of isoaspartyl residues in blood plasma proteins. J Alzheimers Dis 27, 113-118.
18. Griss J, Mart'in M, O'Donovan C, Apweiler R, Hermjakob H, Vizca'ino JA (2011) Consequences of the discontinuation of the International Protein Index (IPI) database and its substitution by the UniProtKB "complete proteome" sets. Proteomics 11, 4434-4438.
19. Broadhurst DI, Kell DB (2006) Statistical strategies for avoiding false discoveries in metabolomics and related experiments. Metabolomics 2, 171-196. (Pubitemid 46099798)
20. Fawcett T (2006) An introduction to ROC analysis. Pattern Recogn Lett 27, 861-874.
21. Haw R, Hermjakob H, D'Eustachio P, Stein L (2011) Reactome pathway analysis to enrich biological discovery in proteomics data sets. Proteomics 11, 3598-3613.
22. Miike K, Aoki M, Yamashita R, Takegawa Y, Saya H, Miike T (2010) Proteome profiling reveals gender differences in the composition of human serum. Proteomics 10, 2678-2691.
23. Corzett TH, Fodor IK, Choi MW, Walsworth VL, Turteltaub KW,McCutchen-Maloney SL, Chromy BA (2010) Statistical analysis of variation in the human plasma proteome. J Biomed Biotechnol 2010, 258494.
24. Ganrot PO, Scherst́enB(1967) Serum2-macroglobulin concentration and its variation with age and sex. Clinica Chimica Acta 15, 113-120.
25. Blacker D,Wilcox MA, Laird NM, Rodes L, Horvath SM, Go RC, Perry R, Watson B Jr, Bassett SS, McInnis MG, Albert MS, Hyman BT, Tanzi RE (1998) Alpha-2 macroglobulin is genetically associated with Alzheimer disease. Nat Genet 19, 357-360. (Pubitemid 28357907)
26. Akuffo EL, Davis JB, Fox SM, Gloger IS, Hosford D, Kinsey EE, Jones NA, Nock CM, Roses AD, Saunders AM, Skehel JM, Smith MA, Cutler P (2008) The discovery and early validation of novel plasma biomarkers in mild-to-moderate Alzheimer's disease patients responding to treatment with rosiglitazone. Biomarkers 13, 618-636.
27. Lundstrom SL, Yang H, Lyutvinskiy Y, Rutishauser D, Herukka SK, Soininen H, Zubarev RA (2013) Blood plasma IgG Fc glycans are significantly altered in Alzheimer's disease and progressive mild cognitive impairment. J Alzheimers Dis 38, 567-579.
28. Hall JR, Johnson LA, Barber RC, Vo HT, Winter AS, O'Bryant SE (2012) Biomarkers of basic activities of daily living in Alzheimer's disease. J Alzheimers Dis 31, 429-437.
29. Cortes-Canteli M, Zamolodchikov D, Ahn HJ, Strickland S, Norris EH (2012) Fibrinogen and altered hemostasis in Alzheimer's disease. J Alzheimers Dis 32, 599-608.
30. Wang Y, Hancock AM, Bradner J, Chung KA, Quinn JF, Peskind ER, Galasko D, Jankovic J, Zabetian CP, Kim HM, Leverenz JB, Montine TJ, Ginghina C, Edwards KL, Snapinn KW, Goldstein DS, Shi M, Zhang J (2011) Complement 3 and factor h in human cerebrospinal fluid in Parkinson's disease, Alzheimer's disease, and multiple-system atrophy. Am J Pathol 178, 1509-1516.
31. Bonifati DM, Kishore U (2007) Role of complement in neurodegeneration and neuroinflammation. Mol Immunol 44, 999-1010. (Pubitemid 44414994)
32. AiyazM,LuptonMK,Proitsi P, Powell JF,Lovestone S (2012) Complement activation as a biomarker for Alzheimer's disease. Immunobiology 217, 204-215.
33. Thambisetty M, Simmons A, Hye A, Campbell J, Westman E, Zhang Y, Wahlund LO, Kinsey A, Causevic M, Killick R, Kloszewska I, Mecocci P, Soininen H, Tsolaki M, Vellas B, Spenger C, Lovestone S (2011) Plasma biomarkers of brain atrophy in Alzheimer's disease. PLoS One 6, e28527.
34. Squitti R, Salustri C, Siotto M,Ventriglia M,Vernieri F, Lupoi D, Cassetta E, Rossini PM (2010) Ceruloplasmin/transferrin ratio changes in Alzheimer's disease. Int J Alzheimers Dis 2011, 231595.